| Title |
Cost Utility of Tumour Necrosis Factor-α Inhibitors for Rheumatoid Arthritis
|
|---|---|
| Published in |
PharmacoEconomics, December 2012
|
| DOI | 10.2165/11594990-000000000-00000 |
| Pubmed ID | |
| Authors |
Christine M. Nguyen, Mark Bounthavong, Margaret A. S. Mendes, Melissa L. D. Christopher, Josephine N. Tran, Rashid Kazerooni, Anthony P. Morreale |
| Abstract |
Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects approximately 1.5 million people in the US. Tumour necrosis factor (TNF)-α inhibitors have been shown to effectively treat and maintain remission in patients with moderately to severely active RA compared with conventional agents. The high acquisition cost of TNF-α inhibitors prohibits access, which mandates economic investigations into their affordability. The lack of head-to-head comparisons between these agents makes it difficult to determine which agent is the most cost effective. |
Mendeley readers
The data shown below were compiled from readership statistics for 70 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 70 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 15 | 21% |
| Student > Master | 13 | 19% |
| Student > Ph. D. Student | 9 | 13% |
| Student > Bachelor | 6 | 9% |
| Student > Doctoral Student | 6 | 9% |
| Other | 9 | 13% |
| Unknown | 12 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 26 | 37% |
| Pharmacology, Toxicology and Pharmaceutical Science | 9 | 13% |
| Economics, Econometrics and Finance | 6 | 9% |
| Nursing and Health Professions | 4 | 6% |
| Computer Science | 2 | 3% |
| Other | 5 | 7% |
| Unknown | 18 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 September 2017.
All research outputs
#8,262,445
of 25,374,647 outputs
Outputs from PharmacoEconomics
#963
of 1,992 outputs
Outputs of similar age
#84,284
of 289,102 outputs
Outputs of similar age from PharmacoEconomics
#91
of 280 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one has received more attention than most of these and is in the 66th percentile.
So far Altmetric has tracked 1,992 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.6. This one has gotten more attention than average, scoring higher than 50% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 289,102 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.
We're also able to compare this research output to 280 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.